[Growth dynamics of transplantable murine tumors in the course of dicarbamin-protected chemotherapy].
Dicarbamin-assisted mono- and combination chemotherapy (cyclophosphamide + carboplatin + cisplatin) for transplantable tumors born by linear or hybrid mice of both sexes was investigated. It was shown that long-term oral administration contributed to the effect of a range of cytostatic therapeutic dosage rather than adversely affected it. Our findings were used to make a case for clinical studies of dicarbamin for its potential of lowering hematological toxicity of antitumor therapy.
L A
LA
Sedakova
E M
EM
Treshchalina
S M
SM
Sitdikova
V E
VE
Nebol'sin
D000284:Administration, Oral; D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D002208:Caproates; D016190:Carboplatin / Q000009:adverse effects; D049109:Cell Proliferation; D002945:Cisplatin / Q000009:adverse effects; D003520:Cyclophosphamide / Q000009:adverse effects; D005260:Female; D006402:Hematologic Diseases / Q000139:chemically induced / Q000517:prevention & control*; D007093:Imidazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D051379:Mice; D009368:Neoplasm Transplantation; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D020011:Protective Agents / Q000008:administration & dosage / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D002208:Caproates; D007093:Imidazoles; D020011:Protective Agents; C539419:pentanedioic acid imidazolyl ethanamide; D003520:Cyclophosphamide; D016190:Carboplatin; D002945:Cisplatin